Pure red cell aplasia secondary to treatment with erythropoietin

Journal of Nephrology

Volumn 16, Issue 4, 2003, Pages 461-466

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Anti erythropoietin antibodies; Chronic kidney disease; Erythropoietin; Molecular structure; Pure red cell aplasia

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTIBODY; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGYLATED EPOETIN BETA; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; RO 503821; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW; CANCER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOWNSTREAM PROCESSING; DRUG COST; DRUG FORMULATION; DRUG SOLUBILITY; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; HUMAN; IMMUNOGENICITY; INCIDENCE; NONHUMAN; PROBABILITY; PROTEIN GLYCOSYLATION; REVIEW; UNITED STATES;

AUTOANTIBODIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GLYCOSYLATION; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RED-CELL APLASIA, PURE; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 1642435683     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Croisille L, Tchernia G, Casadevall N. Autoimmune disorders of erythropoiesis. Curr Opin Hematol 2001; 8: 68-73.
2. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-9.
3. Lin YW, Okazaki S, Hamahata K, Watanabe K, Usami I, Yoshibayashi M, Akiyama Y, Kubota M. Acute pure red cell aplasia associated with allopurinole therapy. Am J Hematol 1999; 61: 209-11.
4. Vogt B, Fivush BA. Cyclosporin in the treatment of azathioprine-induced red cell aplasia following renal transplantation. Pediatr Nephrol 1992; 6: 278-9.
5. Arbeiter K, Greenbaum L, Balzar E, Muller T, Hofmeister F, Bidmon B, Aufricht C. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 2000; 14: 195-7.
6. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334: 630-3.
7. Kwong YL, Wong KF, Liang RH, Chu YC, Chan LC, Chan TK. Pure red cell aplasia: Clinical features and treatment results in 16 cases. Ann Hematol 1996; 72: 137-40.
8. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
9. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47: 331-5.
10. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoitein. N Engl J Med 2002; 346: 469-75.
11. Weber G, Gross G, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13: 2381-3.
12. Chang WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 2003; 41: 692-5.
13. Montagnac R, Boffa GA, Schillinger F, Guillaumie J. Sensibilisation à l'erythropoiétine humaine recombinante chez une hémodialysée. Presse Med 1992; 21: 84-5.
14. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds. Erythropoietin. Molecular Physiology and Clinical Applications. Marcel Dekker: New York, 1993; 265-73.
15. Peces R, de la Torre M, Alcàzar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anaemia. N Engl J Med 1996; 335: 523-4.
16. European Renal Association-European Dialysis Transplant Association. Erythropoietic proteins and antibody-mediated pure red cell aplasia: Where are we now and where do we go from here? Nephrol Dial Transplant 2003 (in press).
17. Krüger A, Schröer W, Röhrs F, Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant 2003; 18: 1033-4.
18. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-64.
19. Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E, Stebbing N. Eythropoietion: Gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 1986; 51: 693-702.
20. Endo Y, Nagai H, Watanabe Y, Ochi K, Takagi T. Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem 1992; 112: 700-6.
21. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
22. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626-34.
23. Storring PL, Yuen CT, Skibeli V, Nissen-Lie G, Torjesen P. Differences between the N-glycans of human serum erythropoietin and recombinant human erythropoietin. Blood 2003; 101: 1204.
24. Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 2002; 57: 237-45.
25. Egrie JC, Browne KJ. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 (suppl 3): S3-13.
26. Haselbeck A, Tare N, Pill J. Pre-clinical pharmacokinetics and pharmacodynamics of CERA (Continuous erythropoiesis Receptor Activator) indicate a superior new therapy for anemia. Presented at the American Society of Hematology 44th Annual Meeting, December 2002, San Diego, California, US.
27. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Wilken J, Tang J, Levy JJ, Miranda LP, Crnogorac MM, Kalbag S, Botti P, Schindler-Horvat J, Savatski L, Adamson JW, Kung A, Kent SB, Bradburne JA. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003; 299: 884-7.
28. Varki A. Biologic roles of oligosaccharides: All of the theories are correct. Glycobiology 1993; 3: 97-130.
29. Delves PJ. The roe of glycosylation in autoimmune disease. Autoimmunity 1998; 27: 239-53.
30. Lisowska E. The role of glycosylation in protein antigenic properties. Cell Mol Life Sci 2002; 59: 445-55.
31. Munk K, Pritzer E, Kretzschmar E, Gutte B, Garten W, Klenk HD. Carbohydrate masking of an antigenic epitope of influenza viruz haemoagglutinin independent of oligosaccharide size. Glycobiology 1992; 2: 233-40.
32. Sharma B, Vice President EPO Technical Development, Johnson & Johnson, Personal Communication at the American Society of Nephrology-2002 Annual Meeting, 1-4 November 2002, Philadelphia, USA.
33. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
34. Casadevall N. Personal Communication at the Meeting "Optimizing Anaemia Management", Munich, Germany, 8 March, 2003.